Keros Therapeutics Approves $5 Million Buyback After Drug Milestone Payment
By Katherine Hamilton
Keros Therapeutics approved up to a $5 million share buyback.
The buyback, approved by the board, follows the receipt of a $20 million development milestone payment under Keros' license agreement with Takeda Pharmaceuticals.
The milestone is for elritercept, a drug being developed as a blood platelet producer, which finished dosing the first patient in a clinical trial.
The new buyback approval can be modified or discontinued at any time.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
November 16, 2026 18:00 ET (23:00 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?

